Quantcast
 
New book by Larry Connors Click here Improve your trading - See how


 

DATATRAK International, Inc. Announces First Quarter Results for 2009

Wed. May 13, 2009; Posted: 04:00 PM
Stocks RSS
CLEVELAND, May 13, 2009 /PRNewswire-FirstCall via COMTEX/ -- DATA | Quote | Chart | News | PowerRating -- DATATRAK International, Inc. (Nasdaq: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced its operating results for the first quarter of 2009.

Revenue for the first quarter of 2009 remained relatively constant at $2,086,000 compared to $2,088,000 in the same period of 2008. Gross profit margin improved to 77% for the three months ended March 31, 2009 compared to 55% for the first three months of 2008. The improvement in the Company's gross margin reflects a 49% reduction in direct costs.

For the three months ended March 31, 2009, DATATRAK's loss from operations was $(787,000) compared to $(2,225,000) in the first quarter of the prior year. The current year first quarter loss of $(787,000) includes $634,000 of severance charges related primarily to the separation of two executive officers of the Company. Selling, general and administrative expenses decreased approximately $1.2 million in the first quarter of 2009 compared to the first quarter of 2008. Excluding severance charges from both comparable periods, DATATRAK's loss from operations would be $(153,000) in the current year first quarter compared to $(2,199,000) in the same period last year. Net loss for the first quarter of 2009 was $(788,000), or $(0.06) per share on both a basic and diluted basis compared to $(2,233,000) in the first quarter of 2008, or $(0.16) per share on both a basic and diluted basis.

"We are very pleased with our first quarter results, which we believe reflect our continuing efforts to optimize our operating structure," commented Laurence P. Birch, Chairman of the Board and interim-Chief Executive Officer of the Company. "Excluding severance charges, our operating loss for the quarter was only $(153,000) compared to an operating loss of $(2,199,000) in last year's first quarter. This marks our second consecutive quarter of reaching nearly break-even results, and we believe this is an important milestone that we look forward to sharing at the DIA show in San Diego next month. Our cash balance has remained relatively constant, decreasing by only $294,000 this quarter compared to a cash decrease of $2.6 million in the first quarter of 2008. The $294,000 decrease includes the payout of approximately $150,000 for severance commitments. While our current severance commitments are significant, we believe building a strong, experienced management team is imperative to positioning the Company for success, and in turn, driving long-term shareholder value."

About DATATRAK International, Inc.

DATATRAK International, Inc. is a worldwide technology company focused on the provision of multi-component eClinical solutions and related services for the clinical trials industry. The Company delivers a complete portfolio of software products that were created in order to accelerate clinical research data from investigative sites to clinical trial sponsors and ultimately the FDA, faster and more efficiently than manual methods or loosely integrated technologies. The DATATRAK eClinical(TM) software suite can be deployed worldwide through an ASP offering or in a licensed Enterprise Transfer model that fully empowers its clients. The DATATRAK software suite and its earlier versions have successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 59 countries. DATATRAK International, Inc.'s product suite has been utilized in some aspect of the clinical development of 16 drugs and one medical device that have received regulatory approval from either the United States Food and Drug Administration or counterpart European bodies. DATATRAK International, Inc. has offices located in Cleveland, Ohio, and Bryan, Texas. Its common stock is listed on the NASDAQ Stock Market under the ticker symbol "DATA". Visit the DATATRAK International, Inc. web site at www.datatrak.net.

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors (including those specified below) which are difficult to predict and, in many instances, are beyond the control of the Company. Factors that may cause actual results to differ materially from those in the forward-looking statements include the limited operating history on which the Company's performance can be evaluated; the ability of the Company to continue to enhance its software products to meet customer and market needs; fluctuations in the Company's quarterly results; the viability of the Company's business strategy and its early stage of development; the timing of clinical trial sponsor decisions to conduct new clinical trials or cancel or delay ongoing trials; the Company's dependence on major customers; government regulation associated with clinical trials and the approval of new drugs; the ability of the Company to compete in the emerging EDC market; losses that potentially could be incurred from breaches of contracts or loss of customer data; the inability to protect intellectual property rights or the infringement upon other's intellectual property rights; the Company's success in integrating its acquisition's operations into its own operations and the costs associated with maintaining and/or developing two product suites; delisting of the Company's common shares from the NASDAQ Capital Market; and general economic conditions such as the rate of employment, inflation, interest rates and the condition of capital markets. This list of factors is not all-inclusive. In addition, the Company's success depends on the outcome of various strategic initiatives it has undertaken, all of which are based on assumptions made by the Company concerning trends in the clinical research market and the health care industry. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.

                    DATATRAK International, Inc. and Subsidiaries
                      Condensed Consolidated Balance Sheet Data
                                      (Unaudited)

                                       March 31, 2009  December 31, 2008
                                       --------------  -----------------
    Cash and investments                   $2,077,513         $2,372,294
    Restricted cash - current                       -            218,276
    Accounts receivable, net                1,187,661            927,490
    Property & equipment, net                 679,803            785,549
    Deferred tax assets                       136,500            145,400
    Other                                     232,815            198,131
                                              -------            -------
       Total assets                        $4,314,292         $4,647,140
                                           ==========         ==========

    Accounts payable and other current
     liabilities                           $2,008,149         $1,825,735
    Deferred revenue - current              1,103,807          1,053,096
    Long-term liabilities                   1,669,823          1,446,923
    Shareholders' equity                     (467,487)           321,386
                                            ---------            -------
       Total liabilities and
        shareholders' equity               $4,314,292         $4,647,140
                                           ==========         ==========



                 DATATRAK International, Inc. and Subsidiaries
                Condensed Consolidated Statements of Operations
                                  (Unaudited)

                                          For the Three Months Ended March 31,
                                          ------------------------------------
                                                2009                2008
                                                ----                ----
    Revenue                                 $2,086,176          $2,088,229
    Direct costs                               473,862             933,879
                                               -------             -------
       Gross profit                          1,612,314           1,154,350

    Selling, general and
     administrative expenses                 1,643,577           2,830,757
    Severance expense                          633,625              25,843
    Depreciation and amortization              121,976             522,426
                                               -------             -------
       Loss from operations                   (786,864)         (2,224,676)

    Interest income                              3,003              59,740
    Interest expense                             4,008              66,567
    Other loss                                       -               1,382
                                                   ---               -----
       Loss before income taxes               (787,869)         (2,232,885)

    Income tax expense                               -                   -
                                                   ---                 ---
       Net loss                              $(787,869)        $(2,232,885)
                                            ==========        ============
         Net loss per share:
              Basic:
              Net loss per share                $(0.06)             $(0.16)
                                               =======             =======
              Weighted-average shares
               outstanding                  13,741,401          13,681,901
                                            ==========          ==========
              Diluted:
              Net loss per share                $(0.06)             $(0.16)
                                               =======             =======
              Weighted-average shares
               outstanding                  13,741,401          13,681,901
                                            ==========          ==========


SOURCE DATATRAK International, Inc.

http://www.datatrak.net
For full details for DATA click here.

    


More News:   Market Updates | Stock Alerts | All Trading News | Stock Index

Email
Print
Archives
Feedback
Email Article Link
Close X
Recipients email address
Your name
Your email
Add a note (optional)




Stocks RSS





Most Popular News
  UPCOMING EVENTS
Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.
* Attendance is strictly limited and are filled on a first-come, first-served basis.
PREMIER SPONSORED LINKS
TRADE CENTER
 
The TradingMarkets Directory
RELATED SITES
Nothing but forex
Please call 1-213-955-5858 ext. 1

About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302

© Copyright 2009 The Connors Group, Inc.


All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.

© 2009 The Connors Group, Inc.